ursodiol

(redirected from Urso 250)

ursodiol

 [ur″so-di´ol]
the secondary bile acid ursodeoxycholic acid used as an anticholelithic to dissolve radiolucent, noncalcified gallstones.

ur·so·di·ol

(ŭr'sō-dī'ōl),
A bile acid used to facilitate the dissolution of gallstones in patients; a potential alternative to cholecystectomy.

ursodiol

/ur·so·di·ol/ (ur″so-di´ol) the secondary bile acid ursodeoxycholic acid used as an anticholelithic to dissolve radiolucent, noncalcified gallstones.

ursodiol

Actigall®, ursodeoxycholic acid Hepatology A pharmacologic preparation of ursodeoxylcholic acid, a 2º bile acid, used to dissolve bile gallstones and manage primary biliary cirrhosis. See Primary biliary cirrhosis.

ur·so·di·ol

(ŭr'sō-dī'ōl)
A bile acid used to facilitate the dissolution of gallstones in patients; a potential alternative to cholecystectomy.
Synonym(s): ursodeoxycholic acid.

ursodiol,

n brand names: Actigall, Ursofalk;
drug class: gallstone solubilizing agent;
action: suppresses hepatic synthesis, secretion of cholesterol; inhibits intestinal absorption of cholesterol;
uses: dissolution of radiolucent noncalcified gallstones of less than 20 mm in diameter, in which surgery is not indicated.
References in periodicals archive ?
2 n/a n/a n/a (1) Based on IMS Prescription data for products sold in the United States, as compared to the same period a year earlier (2) For sales of URSO 250 and URSO Forte, in the United States only PRODUCTS IN NORTH AMERICA CANASA
the Authorized Generic version of URSO Forte Scored and URSO 250.
URSO 250 and URSO Forte Scored are approved by the Food and Drug Administration for the treatment of patients with Primary Biliary Cirrhosis (PBC), a chronic liver disease that slowly destroys the ducts that drain bile in the liver.
2% of all gastrointestinal prescriptions for ursodiol in the United States were for URSO 250, making URSO 250 the most prescribed "branded" ursodiol in the U.
We are already the market leader in North America, where we have been selling URSO 250 since 1997 and we will now hold a similar position in France.
A recently completed study at the Mayo Clinic demonstrated that a single dose of URSO 500 is as effective as two separate URSO 250 doses; therefore, Axcan believes that the new URSO 500 formulation will replace URSO 250 and will improve patient compliance with therapy.
Axcan markets a broad line of pharmaceutical products used in the treatment of a variety of gastro-intestinal diseases and disorders, such as URSO 250 for the treatment of certain cholestatic liver diseases, ULTRASE for the treatment of certain gastro-intestinal symptoms related to cystic fibrosis, SALOFALK and CANASA for the treatment of certain inflammatory bowel diseases and PHOTOFRIN for the treatment of certain cancers of the esophagus.
Axcan incurred this debt in November 1999, as a result of the purchase by Axcan of Schwarz's 50% interest in Axcan URSO LLC, a joint-venture created in January 1997, for the purpose of marketing URSO 250 in the United States.
These increases are mainly due to the additions of field sales force representatives in the United States, to increased marketing efforts following the integration of URSO 250 and VIOKASE in Axcan Scandipharm's product line, to the acquisition of world-wide rights to PHOTOFRIN as well as to the newly initiated marketing of CANASA 500 mg suppositories in the United States.
This increase is mainly due to the additions made to the sales force in the United States and to an increased marketing effort following the integration of URSO 250 and VIOKASE in Axcan Scandipharm's product line and the acquisition of the world-wide rights to PHOTOFRIN.
Moreover, due to the fact that recently completed Phase II trials have shown URSO 250 to have no effect in reducing cholesterol, we have decided to focus our development efforts on preventing the recurrence of colorectal polyps and on the treatment of liver diseases.